Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
National Vaccine And Serum Institute (Nvsl) maintains a company patent portfolio within the Biotechnology & Pharmaceuticals technology area. The portfolio currently contains 1 pending office action. This action is assigned to 1 distinct examiner, JADHAO, SAMADHAN JAISING, who is the busiest examiner for the company. The prosecution activity is situated within 1 distinct art unit. JADHAO, SAMADHAN JAISING is responsible for the 1 busiest examiner pending action.
The involvement of 1 distinct examiner means that the outcome of the pending portfolio is subject to the review of JADHAO, SAMADHAN JAISING. This structure in 1 distinct art unit defines the prosecution strategy. Practitioners should note that the company's patent trajectory is tied to this point of review. The presence of 1 pending office action indicates the phase of intellectual property development for the company. The 1 distinct examiner and 1 distinct art unit represent the scope of the portfolio's engagement with the patent office. Because only 1 distinct art unit is involved, the technical focus is limited to the subject matter handled by that unit. The 1 pending office action constitutes the total active workload for the company in the Biotechnology & Pharmaceuticals area. This concentration in a single art unit and examiner suggests a concentrated approach to patenting.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| JADHAO, SAMADHAN JAISING | 1 | 46.2% | +47.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18275226 | S-RBD Trimer Protein Vaccine for Novel Coronavirus and Preparation Method and Application Therefor | JADHAO, SAMADHAN JAISING | 47d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18275226 | S-RBD Trimer Protein Vaccine for Novel Coronavirus and Preparation Method and Application Therefor | JADHAO, SAMADHAN JAISING | 47d |
| Art Unit | Apps |
|---|---|
| 1672 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18275226 | S-RBD Trimer Protein Vaccine for Novel Coronavirus and Preparation Method and Application Therefor | JADHAO, SAMADHAN JAISING | 1672 | §102§103Other | Final Rejection | 47d | Pending | Aug 01, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialNational Vaccine And Serum Institute (Nvsl) has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Samadhan Jaising Jadhao has the most, with 1 of National Vaccine And Serum Institute (Nvsl)'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
